160 related articles for article (PubMed ID: 16551862)
1. 5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
McKeage MJ; Fong P; Jeffery M; Baguley BC; Kestell P; Ravic M; Jameson MB
Clin Cancer Res; 2006 Mar; 12(6):1776-84. PubMed ID: 16551862
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
Li J; Jameson MB; Baguley BC; Pili R; Baker SD
Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial.
Jameson MB; Baguley BC; Kestell P; Zhao L; Paxton JW; Thompson PI; Waller S;
Cancer Chemother Pharmacol; 2007 Apr; 59(5):681-7. PubMed ID: 17021822
[TBL] [Abstract][Full Text] [Related]
4. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
5. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Zhao L; Ching LM; Kestell P; Baguley BC
Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
[TBL] [Abstract][Full Text] [Related]
6. Transient retinal effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA, ASA404), an antitumor vascular-disrupting agent in phase I clinical trials.
Jameson MB; Sharp DM; Sissingh JI; Hogg CR; Thompson PI; McKeage MJ; Jeffery M; Waller S; Acton G; Green C; Baguley BC
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2553-9. PubMed ID: 19387077
[TBL] [Abstract][Full Text] [Related]
7. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
[TBL] [Abstract][Full Text] [Related]
8. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ; Reck M; Jameson MB; Rosenthal MA; Gibbs D; Mainwaring PN; Freitag L; Sullivan R; Von Pawel J
Lung Cancer; 2009 Aug; 65(2):192-7. PubMed ID: 19409645
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
12. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Baguley BC; Zhuang L; Kestell P
Oncol Res; 1997; 9(2):55-60. PubMed ID: 9167186
[TBL] [Abstract][Full Text] [Related]
13. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Zhou S; Kestell P; Tingle MD; Paxton JW
Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours.
Cheeseman SL; Brannan M; McGown A; Khan P; Gardner C; Gumbrell L; Dickens D; Ranson M
Br J Cancer; 2000 Dec; 83(12):1599-606. PubMed ID: 11104552
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
17. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.
Liu JJ; Ching LM; Goldthorpe M; Sutherland R; Baguley BC; Kirker JA; McKeage MJ
Cancer Chemother Pharmacol; 2007 Apr; 59(5):661-9. PubMed ID: 16944150
[TBL] [Abstract][Full Text] [Related]
18. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
[TBL] [Abstract][Full Text] [Related]
19. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
[TBL] [Abstract][Full Text] [Related]
20. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Galbraith SM; Rustin GJ; Lodge MA; Taylor NJ; Stirling JJ; Jameson M; Thompson P; Hough D; Gumbrell L; Padhani AR
J Clin Oncol; 2002 Sep; 20(18):3826-40. PubMed ID: 12228202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
